

Your article has been submitted 31645

66.

Dari: research@f1000.com

Kepada: erwintriyono@yahoo.com

Tanggal: Rabu, 23 Desember 2020 12.13 WIB

Dear Erwin Astha

Tri Pudy Asmarawati has submitted this manuscript:

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya

Tri Pudy Asmarawati *et al.* with Tri Pudy Asmarawati, Alfian Nur Rosyid as the corresponding author(s).

Funders: no grant funding was stated during submission.

Before accepting the article: we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

Before publishing the article: if we accept the article, we will be in touch with Tri Pudy Asmarawati as soon as possible with any issues that need addressing and ask them for reviewer suggestions. They will then receive a final proof of the article for approval, prior to publication. At that stage, the peer review process will begin, in accordance with our publishing model.

After publication: to ensure you receive proper recognition for your professional activities, you can connect your **ORCID ID** to F1000Research so that all your F1000Research work is added to your account automatically once it is published. Details on how to do this will be sent in an email when the article is published.

All future correspondence about this submission will be sent to Tri Pudy Asmarawati only. If you have not agreed to this submission and your inclusion as an author of this article, please contact us immediately quoting the article number: 31645.

Kind regards

The F1000Research Team

Press releasing articles: Please avoid promoting articles in the media until the article has passed the open peer review process. Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Your article is published

Dari: production@f1000research.com

Kepada: erwintriyono@yahoo.com

Tanggal: Senin, 15 Februari 2021 22.45 WIB

Dear Erwin Astha,

Your article: "The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya" has just been published on F1000Research - you can maximize its reach by using the Email and Share options on the article page.

To ensure you receive proper recognition for your professional activities, connect your ORCID iD to F1000Research so that all your work is added to your account automatically (*this is a personalised link – please do not click unless this email was originally addressed to you*): [Connect your existing account](#) | [Create an account](#)

We are now inviting the reviewers that have been suggested by the submitting author of your article, Tri Pudy Asmarawati. Reviewers are asked to provide a status of 'Approved', 'Approved with Reservations' or 'Not Approved', and a peer review report that will be published alongside the article under their name and affiliation. You will be able to respond to any published peer review reports with a comment and/or publish revisions as a new version of your article, as appropriate.

Please note that we will have to ask Tri Pudy Asmarawati for additional suggestions if the invited reviewers decline. To monitor the peer review status of your article, please liaise with Tri Pudy Asmarawati for updates.

Regards

Zena Nyakoojo
Senior Managing Editor, F1000Research

Press releasing articles: Please avoid promoting articles in the media until the article has passed the open peer review process. Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Fwd: Your article 31645 is now accepted

5 - Gd

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 05.02 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 9 April 2023 04.59.14 GMT+7
To: erwintriyono@yahoo.com
Subject: Fwd: Your article 31645 is now accepted

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.30.18 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: Your article 31645 is now accepted

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 3 February 2021 14.50.29 GMT+7
To: editorial@f1000research.com
Subject: Re: Your article 31645 is now accepted

Dear Editor

We are glad that our paper can be accepted for publication. Thank you for the work.

Best regards,
Tri Pudy

On 3 Feb 2021, at 10.34, editorial@f1000research.com wrote:

Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

Dear Tri Pudy

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya
Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, Arifianto MV, Bramantono B *et al.*

We have now accepted your article for publication in F1000Research. It will be sent to the typesetters and a member of the Production team will send you a proof in due course.

One of our editorial team will be assisting you with the peer review process of your article, and will be your main contact once the article is published.

Best wishes,

Elizabeth
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Fwd: Manuscript 31645 conditionally accepted for publication

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 05.01 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 9 April 2023 04.58.56 GMT+7
To: erwintriyono@yahoo.com
Subject: Fwd: Manuscript 31645 conditionally accepted for publication

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.26.09 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: Manuscript 31645 conditionally accepted for publication

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 28 January 2021 07.47.23 GMT+7
To: bagus aulia <bagus.aulia.mahdi-2018@fk.unair.ac.id>
Subject: Fwd: Manuscript 31645 conditionally accepted for publication

Sent from my iPhone

Begin forwarded message:

From: "F1000.Research" <research@f1000.com>

Date: 28 January 2021 07.16.26 GMT+7
To: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Subject: RE: Manuscript 31645 conditionally accepted for publication

Dear Tri Pudy,

Thank you for sending in your revisions. There are a few remaining queries on your article:

- Please confirm that the following consent statement I have included for you is correct: Written informed consent was obtained from the participants prior to the start of the study.
- Please confirm that you have permission from those you wish to acknowledge in the manuscript to name them in the article.

Best regards,

Molly

Molly Cranston
Editorial Lead (STM)

F1000 Research Ltd | Email: molly.cranston@f1000.com

240 Blackfriars Rd, London, SE1 8BU

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Sent: Friday, 22 January 2021 2:57 PM
To: F1000.Research <research@f1000.com>
Subject: Re: Manuscript 31645 conditionally accepted for publication

Dear editor,

Thankyou for replying our email

We are here to submit our revised manuscript for submitting this journal

We are very pleased to know that our manuscript can be accepted

Here to inform you the address of repository:

Asmarawati, Tri Pudy et al. (2021), The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya, Dryad, Dataset, <https://doi.org/10.5061/dryad.sxksn0328>

Share Link: <https://datadryad.org/stash/share/MApd0-zS5KcEXZLpGNZh6YoQmB7MXpBkZbcUpcSYrpM>

For coauthor email address: vitanatadr@gmail.com

We dont have any code for RRID, because our data source from medical history

We have completed the APC (article processing charge)

Best Regards.

Tri Pudy Asmarawati

Pada tanggal Rab, 20 Jan 2021 pukul 21.16 <research@f1000.com> menulis:

Dear Tri Pudy

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya
Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, Arifianto MV, Bramantono B *et al.*

Thank you for your submission to F1000Research. We have noted a few issues with your manuscript (below) – once these are addressed we will be pleased to accept your article for publication.

Content: We endorse the **STROBE** guidelines for reporting of meta-analysis research studies; we suggest that you ensure the article adheres to the checklist and add any details that are missing. In addition:

- ensure the initials added to the author names are correct.
- ensure the abbreviations, where full descriptions are added, are correct
- consider adding references where requested
- recommend adding the supplemental files (3 tables and 2 figures) to the manuscript for publication. If these files remain as supplemental files they will need to be submitted to an online repository as extended data
- add more details of consent required to use data from the medical records

Research Resource Identifiers (RRIDs): We encourage you to add [RRIDs](#) in order to identify the bacteria that are included in your article. More information on this project is available from the Resource Identification Initiative and RRIDs can be obtained from the portal.

Data availability: Our publication model requires that we always ask the author to provide the raw data that support their findings. We believe that it is essential that others can see the raw data to be able to replicate your study and re-analyse and/or reuse the data (with appropriate attribution).

We ask that authors submit their underlying/extended data to an online repository. More information can be found on [our data guidelines page](#).

With your submission you have included two data files that need to be submitted to an online repository as underlying data. Before the files are submitted to a repository the text in the spreadsheets needs to be translated into English and data labels added to the sheets in each.

When submitting data to an online repository, please ensure you create a DOI, which will be stated and cited in the Data availability section of the manuscript. Please include the name of the repository and the DOI in the Data availability section, along with the license the data is held under (please make sure that you choose a license when submitting your data to a repository – we would strongly suggest a CC0 license).

If you are submitting data to Open Science Framework, please register your project to ensure that a record of this project will remain persistent and unchangeable (an open-ended registration is usually the most appropriate). Once you have registered your project, please create a DOI for this registration by clicking the pencil icon next to 'Registration DOI'. This DOI will be stated and cited in the Data availability section of the manuscript.

To ensure you and your co-authors receive appropriate credit for generating your datasets, please ensure you include the names of all authors involved in producing the data. To maximise the likelihood of your data being cited correctly, we strongly encourage you to link the ORCIDs of every author involved in generating the data, where possible.

Please make sure that data is deidentified prior to uploading according to the Safe Harbour method.

Co-author email address: The email address for Muhammad Vitanata Arifianto bounced drvitanata@gmail.com. Please could you provide an alternative email address for Muhammad Vitanata Arifianto so that we can contact them about the submission.

Reviewers: As you know, F1000Research operates an author-driven publication model. This means that you will be responsible for suggesting suitable reviewers, whom we invite on your behalf, giving you an opportunity to ensure that appropriate experts review your article. Our transparent peer review process means that the peer review reports, together with the reviewers' names, will be published alongside your article.

To avoid delay to the publication process, we need you to provide us with at least five potential reviewers who meet our reviewer criteria before we can publish your article - please be aware that it is likely we will need to request further reviewer suggestions after publication. Please go to your [Suggest Reviewers](#) page, where you will find a useful tool to help you find reviewers; use this page to track the progress of the peer review process for your article. You can access this page directly via the article's record under My Research >> Submissions. See also our [reviewer criteria and tips for finding reviewers](#).

Please remember that suggested reviewers should have appropriate level of experience and the right expertise to judge your article; they must be able to provide an unbiased report (e.g. they must not be recent collaborators or colleagues in your institute). All reviewer suggestions are checked by the editorial team and will be rejected if they do not meet our criteria.

Payment: As F1000Research is open access, we will require payment of the Article Processing Charge (APC) to be able to complete the processing of your submission. The APC is \$1350.00 after any discounts you are eligible for have been applied. **Please provide us with the details of the individual/organization taking responsibility for paying the fee as soon as possible.** Please sign in with the credentials you used to submit the article or you will not be able to access this page. Our Accounts department will be in touch regarding payment.

We have also lightly copyedited your article - please [download the document](#) and check you are happy with the amendments and **then address the queries detailed above using track changes in Word. Please return your revised manuscript to the e-mail address above.** Please note that this is your final opportunity to make any changes to the content of your manuscript. Once the typeset PDF of your manuscript has been created, we will send you a final PDF proof for checking prior to publication.

Best wishes,

Elizabeth
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.
Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

Information Classification: General

Fwd: Article submission received

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 05.01 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 9 April 2023 04.58.39 GMT+7
To: erwintriyono@yahoo.com
Subject: Fwd: Article submission received

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.25.41 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: Article submission received

Sent from my iPhone

Begin forwarded message:

From: research@f1000.com
Date: 23 December 2020 12.13.07 GMT+7
To: tpasmarawati@fk.unair.ac.id
Subject: Article submission received

Dear Tri Pudy

Thank you for submitting your manuscript:

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya
Asmarawati TP *et al.*

Funders: no grant funding was stated during submission.

As of 1st September 2020, Article Processing Charges (APCs) on F1000Research are based on article type rather than article length. Charges are payable once the article has been accepted for publication. A full explanation of the price transparency breakdown for the article type categories is available [here](#).

WHAT WE DO NEXT

Before accepting your article: we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

Before publishing your article: if we accept your article, we will be in touch as soon as possible with any issues that need addressing. You will then receive a final proof of your article for approval, prior to publication.

WHAT YOU NEED TO DO NEXT

Before doing anything else, we need you to suggest **at least 5** suitable reviewers to peer review your manuscript following publication (in accordance with our [publishing model](#)), should it be accepted. We ask that authors do not contact reviewers directly about the peer review process. We will need your reviewer suggestions before we can publish the article so we recommend identifying them now via your [Suggest Reviewers](#) page for this article. You can also access this page via the article's record at [My Research >> Submissions](#).

Please quote the article number 31645 in any correspondence.

Kind regards

The F1000Research Team

Press releasing articles: Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Fwd: New version of your article 31645

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 05.01 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.34.24 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: New version of your article 31645

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 25 March 2021 18.07.16 GMT+7
To: bm 101185 <bm101185@gmail.com>
Subject: Fwd: New version of your article 31645

Begin forwarded message:

From: editorial@f1000research.com
Subject: New version of your article 31645
Date: 25 March 2021 17.40.32 GMT+7
To: tpasmarawati@fk.unair.ac.id

Do not delete (filing code): F1KR00CDE F1R-VER55357-A (end code)

Dear Tri Pudy

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya
Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, Arifianto MV, Bramantono B *et al.*

The new version of your F1000Research article is now ready for publication. It will be sent to the typesetters, and a member of the Production team will send you a proof in due course.

Best regards,

The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Fwd: Peer review report published - article has not yet passed peer review

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 05.00 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.34.06 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: Peer review report published - article has not yet passed peer review

Sent from my iPhone

Begin forwarded message:

From: editorial@f1000research.com
Date: 23 March 2021 17.08.21 GMT+7
To: tpasmarawati@fk.unair.ac.id
Subject: Peer review report published - article has not yet passed peer review

Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

Dear Tri Pudy

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya
Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, Arifianto MV, Bramantono B *et al.*

We have published another peer review report for your article in F1000Research at <https://f1000research.com/articles/10-113/v1#referee-response-81317>.

You have now received 2 peer review reports. Some of your reviewers had reservations and therefore your article has not yet passed peer review, which prevents it being indexed in bibliographic databases. (*Once an article receives two 'Approved' statuses, or two 'Approved with Reservations' statuses and one 'Approved' status, it will be considered to have passed peer review.*)

Please let us know how you'd like to proceed:

1) You can revise your article and publish a new version, together with a response to the reviewers. We will then contact the reviewers again for comments on your revision and an updated approval status.

For information on how to submit a new version, please visit [Article Guidelines \(new versions\)](#). Please bear in mind that new submissions need to be created and submitted using the submitting author's account.

2) Alternatively, if you wish to continue with the peer review and try to receive further reviewers opinions before you revise, please continue to suggest additional reviewers, via your [Suggest Reviewers](#) page, where you will find a useful tool to help you find reviewers; you can also access this page via the article's record under My Research >> Submissions.

It is your decision which option you wish to pursue. If we do not hear otherwise, we assume that you are revising and look forward to hearing from you when you are ready with your submission.

If you wish to respond directly to the reviewer by adding a comment to their report (now, or at a later stage), please click the 'Respond to this report' button below the report. When responding to a peer review report, please try and make sure you are logged into the account that you originally used for the submission of this article, otherwise we cannot identify your response as being from an author. Please allow up to one working day for your comment to appear (comments explaining changes in the revised version of your article are usually published at the same time as the revised version).

Best regards,

Jeniffer
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Fwd: Thank you for submitting a new version of your article

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 05.00 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.33.46 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: Thank you for submitting a new version of your article

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 22 March 2021 19.36.43 GMT+7
To: BM 101185 <bm101185@gmail.com>
Subject: Fwd: Thank you for submitting a new version of your article

Gus, nanti sebelum submit kita ketemuan dulu utk ngoreksi masing2 revisinya

Begin forwarded message:

From: "F1000.Production.Research" <production.research@f1000.com>
Date: 22 March 2021 18.57.52 GMT+7
To: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Subject: RE: Thank you for submitting a new version of your article

Dear Tri Pudy,

Thanks for sending this over.

I have ran a compare and can see more clearly the changes you have made. Having looked at the changes that you have made, I do not feel that the 'update text' that you provided is sufficient. The update text should summarise the specific changes made from version 1 to version 2. Direct mention should be made to changes in figures, tables, data etc, and should be no longer than 300 words. This text should not be a place where you respond to reviewer comments – so current statements like *'Yes, the bacterial culture examination was done on the suspicious patients only. Please refer to the last sentence of paragraph 8 in the Discussion section'* should not be included in the update text. Please could you amend your update text so that it follows the guidance above and return it to me via email.

Also, throughout your manuscript I can see that you have left responses to the reviewers. I'm afraid they will not be able to see these response. For reviewers to read these responses, you must upload them to the article page. To upload responses to peer review reports, please visit the article page and click "read" under the Reviewer report in the Open Peer Review box on the right-hand side of the article. Click "Respond to this report" at the end of the report to upload your response.

Please let me know if you require further clarification on any of this.

Kind regards,


Lois Elliott
Business Administrator Apprentice
F1000 Research Ltd (<https://f1000research.com/>)
Email: lois.elliott@f1000.com
240 Blackfriars Rd, London, SE1 8BU, UK

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Sent: 20 March 2021 00:52
To: F1000.Production.Research <production.research@f1000.com>
Subject: Re: Thank you for submitting a new version of your article

Dear editor


Thank you for your email reply.
We resent the revised manuscript with track changes once again.
We try our best to do it so you can know minor changes that have been made and more accurately see all the changes from the previous version.
Answer and respond for the reviewer, Fitriana Eka Murriyawati we wrote in comment.
Hopefully this revised can be accepted and progress to next step.

Best wishes
Tri Pudy Asmarawati and Research Team

 Virus-free. www.avg.com

Pada tanggal Jum, 19 Mar 2021 pukul 16.49 F1000.Production.Research <production.research@f1000.com> menulis:

Dear Tri Pudy,
I'm afraid that we still cannot accept this document. All changes must be inputted via track changes – commenting that they have been included will not suffice as I cannot be sure what specifically has been added. Please could you input all of your changes in the same way that you inputted this first change (image below):



Data regarding secondary respiratory infection in COVID-19 patients are still limited in Indonesia even though the cases distribution is still worldwide ~~ata regarding secondary respiratory infection in COVID-19 patients are still limited even though cases distribution is still worldwide.~~ Several reports suggest that secondary infection will impact the patient's survival and increase intensive care unit (ICU) treatment ¹. COVID-19 pneumonia itself is

If you're having issues with using track changes please let me know and I will do my best to assist.

Kind regards,
Lois Elliott
Business Administrator Apprentice
F1000 Research Ltd (<https://f1000research.com/>)
Email: lois.elliott@f1000.com
240 Blackfriars Rd, London, SE1 8BU, UK

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Sent: 18 March 2021 15:31
To: F1000.Production.Research <production.research@f1000.com>
Subject: Re: Thank you for submitting a new version of your article

Dear editor

We resent the revised manuscript with track changes have switched on so the editor can accurately see all changes have been made. We note in the manuscript answer and respond for the reviewer comments, Fitriana Eka Murriyawati, and minor changes that have been done. Hopefully our revised manuscript can be accepted.

Best wishes
Tri Pudy Asmarawati and Research Team

 Virus-free. www.avg.com

Pada tanggal Kam, 18 Mar 2021 pukul 21.03 F1000.Production.Research <production.research@f1000.com> menulis:

Dear Tri Pudy,

Thank you for getting back to me.

However, I'm afraid that I still cannot accept this version of the revised manuscript. I see that you have marked the changes by highlighting them. However, we require you to **switch on track changes before** you update the manuscript with your changes – this way we can accurately see all changes that have been made. So please could you download a new copy of the latest published version of your article and switch on track changes before you start to edit.

Kind regards,

Lois Elliott
Business Administrator Apprentice
F1000 Research Ltd (<https://f1000research.com/>)
Email: lois.elliott@f1000.com
240 Blackfriars Rd, London, SE1 8BU, UK

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Sent: 18 March 2021 13:46
To: F1000.Production.Research <production.research@f1000.com>
Subject: Re: Thank you for submitting a new version of your article

Dear editor,

Thank you for letting us informed, we have just revised several points on the manuscript as what the reviewer, named Fitriana Murriya Ekawati, had recommended a couple days ago. We include the latest version of our manuscript down below along with highlighted changes. We also insert our reply to the reviewer, which said:
"We firstly would like to thank you for the kindly comprehensive review of our manuscript. Here's to answer and respond to your questions:

1. Introduction

• We believe that there is no prior investigation linked to this topic ever done before in Indonesia. We added this information in the second and last paragraphs of Introduction

2. Methods

• Yes, the bacterial culture examination was done on the suspicious patients only. Please refer to the last sentence of the paragraph 8 in the Discussion section.

3. Results

• We have enclosed the leucocyte and procalcitonin data of the patients on the table 1 on Result section

4. Discussion

• In the study to come, further investigation can probably be done in the low health-care setting, also bigger concerns on under-diagnosed bacterial co-infection of elderly and immunocompromised patients can be taken into consideration. we added this sentence on the last paragraph of the discussion.
• The implication of the study is that we find the bacterial culture examination necessary in the COVID-19 patients management since the bacterial co-infection might worsen the clinical outcome. Therefore this examination should be conducted when the patient shows signs of infection during the intensive care. We added this sentence in the second paragraph of the introduction.

Furthermore, we also appreciate your suggestions in order to improve the final quality of this manuscript. We are currently working on the minor revisions, proof-reading, and going to submit the latest version it promptly"

Hope this will meet all the requirement and we will receive the final pdf proof soon.

Thanks in advance,
Tri Pudy Asmarawati and research team

 Virus-free. www.avg.com
<image001.jpg>

Pada tanggal Sel, 16 Mar 2021 pukul 21.00 <production.research@f1000.com> menulis:

Dear Tri Pudy

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya
Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, Ariyanto MV, Bramantono B *et al.*

Thank you for submitting a new version of your article to F1000Research. We have noted a few minor issues with your manuscript (below) – once these are addressed we will proceed with the publication of this version.

- Please could you make your amendments to the manuscript using the tracked changes function as currently, I'm not able to see what additions/deletions you have made. Please could you send the revised version to us at production.research@f1000.com

Please note that this is the last opportunity to make any changes to the content of your manuscript. Once the typeset PDF of your manuscript has been made, we will send you a final PDF proof for checking prior to publication.

Best regards,

Lois
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.
Do not delete (filing code): F1KR00CDE F1R-VER55357-A (end code)



Information Classification: General

Information Classification: General



Information Classification: General

Fwd: Thank you for submitting a new version of your article **The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya**

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 05.00 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>

Date: 8 April 2023 21.33.04 GMT+7

To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>

Subject: Fwd: Thank you for submitting a new version of your article The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya

Sent from my iPhone

Begin forwarded message:

From: editorial@f1000research.com

Date: 13 March 2021 10.53.33 GMT+7

To: tpasmarawati@fk.unair.ac.id

Subject: Thank you for submitting a new version of your article The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya

Dear Tri Pudy

Thank you for submitting a new version of your article:

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya

Asmarawati TP *et al.*

WHAT WE DO NEXT

We will check your submission to make sure we have all the files and information we need and will be in touch in the next two to three working days. You will receive a final proof of your article for approval, prior to publication. At that point, we usually contact the reviewers who reviewed the previous version of the article for any further comments or changes to the status they originally awarded your article.

WHAT YOU NEED TO DO NEXT

Nothing, just relax and we will be in touch shortly. Don't forget you can track the progress of your article via

My Research >> My Submissions.

Please bear in mind that it is possible the reviewers of your previous version might not be available to review this version. If this is the case and further reviews are required, we will be in touch to discuss the best way to proceed, which may involve asking for further reviewer suggestions.

Please quote the article number 31645 in any correspondence.

Kind regards

The F1000Research Team

Press releasing articles: Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

Do not delete (filing code): F1KR00CDE F1R-VER55357-A (end code)

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Fwd: First peer review report published

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 04.59 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.32.43 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: First peer review report published

Sent from my iPhone

Begin forwarded message:

From: editorial@f1000research.com
Date: 9 March 2021 16.25.51 GMT+7
To: tpasmarawati@fk.unair.ac.id
Subject: First peer review report published

Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

Dear Tri Pudy

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya
Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, Arifianto MV, Bramantono B *et al.*

We have just published a peer review report for your article on F1000Research, which you can read [here](#).

If you wish to respond to the reviewer, please go to the link above and click 'Respond to this report' below the report. When responding to a peer review report, please try and make sure you are logged into the account that you originally used for the submission of this article, otherwise we cannot identify your response as being from an author. Please allow up to one working day for your comments to appear. If you 'Track' the article, you will automatically be alerted to any other reports or comments made.

NB: Your article will pass peer review and be indexed in PubMed, PMC, Scopus, Embase and other indexing sites, if you receive either two 'Approved' statuses, or two 'Approved with Reservations' statuses and one 'Approved' status from the reviewers.

In order to ensure that peer review proceeds quickly and you get at least one more report, we recommend that you suggest additional reviewers. Please visit [Suggest Reviewers](#), where you will find a useful tool to help you find reviewers; you can also access this page via the article's record under My Research >> Submissions. See also our [reviewer criteria and tips for finding reviewers](#).

We would recommend waiting for additional peer review reports before starting on any article revisions.

Best regards,

Jeniffer

The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Fwd: Your article is now published

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 04.59 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.32.02 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: Your article is now published

Sent from my iPhone

Begin forwarded message:

From: production@f1000research.com
Date: 15 February 2021 22.45.12 GMT+7
To: tpasmarawati@fk.unair.ac.id
Subject: Your article is now published

Dear Tri Pudy,

I'm pleased to let you know that your article: "The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya" has just been published on F1000Research.

The Peer Review Process

We are now inviting the reviewers you have suggested. As part of their reports, reviewers are asked to provide a recommendation of 'Approved', 'Approved with Reservations' or 'Not Approved', and their report will be published alongside the article with their full name and affiliation. You will be able to respond to any published reports with a comment and/or by publishing revisions as a new version of your article – we will send you instructions on how to proceed when you begin to receive reports.

It is important that authors do not contact the reviewers directly, as this could result in invalidating their report.

Please note that we will ask you for additional reviewer suggestions if the invited reviewers decline. In order to avoid any delays with the peer review of your article, please continue to check your [Suggest Reviewers](#) page for updates and respond to any email requests as soon as you can.

Linking Your Data

Now that your article has been published and assigned a DOI (10.12688/f1000research.31645.1) we would strongly recommend that you include this DOI in the metadata of any published dataset associated with

this article. If you would like assistance with this, please contact our editorial team.

Increasing Discoverability

Now that your article has been published, why not take advantage of the tools we provide to help maximize your article's reach and share your article using the Email and Share options on the article page.

Your article will be listed in ePMC shortly as a preprint, and then updated once it has passed peer review.

Regards

Zena Nyakoojo
Senior Managing Editor, F1000Research

Press releasing articles: Please avoid promoting articles in the media until the article has passed the open peer review process. Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Fwd: The PDF of your article 31645 is ready for checking

Dari: TRI PUDY (tpasmarawati@fk.unair.ac.id)

Kepada: erwintriyono@yahoo.com

Tanggal: Minggu, 9 April 2023 pukul 04.59 WIB

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 8 April 2023 21.31.39 GMT+7
To: ERWIN ASTHA <erwin.astha@fk.unair.ac.id>
Subject: Fwd: The PDF of your article 31645 is ready for checking

Sent from my iPhone

Begin forwarded message:

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Date: 12 February 2021 08.41.01 GMT+7
To: "F1000.Production.Research" <production.research@f1000.com>
Subject: Re: The PDF of your article 31645 is ready for checking

Dear Editor

Thank you for your email

Yes it is confirmed Figure 3" (page 7) should be changed to say "Figure 2".

Tri Pudy Asmarawati



Virus-free. www.avg.com

Pada tanggal Kam, 11 Feb 2021 pukul 23.21 F1000.Production.Research
<production.research@f1000.com> menulis:

Dear Tri,

Please see the updated PDF draft attached here. Please confirm if "Figure 3" (page 7) should be changed to say "Figure 2"?

Kind regards,

Mahnoor Butt

Deputy Production Manager

F1000 Research Ltd (<https://f1000research.com/>)

Email: mahnoor.butt@f1000.com
240 Blackfriars Rd, London, SE1 8BU, UK

From: TRI PUDY <tpasmarawati@fk.unair.ac.id>
Sent: 09 February 2021 22:45
To: F1000Research.Production <production@F1000Research.com>
Subject: Re: The PDF of your article 31645 is ready for checking

Dear Editor

Thank you for your email, I have corrected some mistakes in your PDF proof and I attached it to this email, I sent you a screenshot of the mistakes and a PDF revised file to easily find the correction. I make a green highlight text for correction in the PDF file.

10588-944.
Preprint Research | [PubMed](https://pubmed.ncbi.nlm.nih.gov/) (last visit: 2020-11-19)

1. Chen X, Luo B, Cheng L, et al. **The microbial co-infection in COVID-19.** *Appl Microbiol Biotechnol*. 2020. **104**(18): 7777-785.
PubMed Abstract | Preprint (not certified by peer review)
2. Boucautier G, Lathé B, Beresford G, et al. **Viral pneumonia.** *Cochrane*. 2021. **3**(7): 1-77.
PubMed Abstract | Preprint (not certified by peer review)
3. Wengocheng A, Bamford CJ. **SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?** *Antimicrob Resist Infect Control*. 2020. **15**(1): e2560.
PubMed Abstract | Preprint (not certified by peer review)
4. Park Young D, Kim JH. **Secondary bacterial infections in critical ill patients with Coronavirus Disease 2019.** *Chest*. 2020. **158**(2): 264-270.
PubMed Abstract | Preprint (not certified by peer review)
5. Sampieri RM. **Clinical Management of COVID-19.** *COVID-19*. 2020. **1**: 9-34.
6. [https://www.pulmonology.com/abstract/S0954-6820\(20\)30114-1](https://www.pulmonology.com/abstract/S0954-6820(20)30114-1)
7. Burhan E, Suwanto AJ, Masitoh SA, et al. **Pendemon Tazalaksana COVID-19.** *Jurnal Agribisnis dan Perikanan Tadulisan COVID-19*. PERAK, PAPUA, PASADIN, PASADIN. 2020. **1**(4): 1-6.
8. Zhou F, Yu T, Du R, et al. **Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study.** *Lancet*. 2020. **395**(10249): 1054-62.
PubMed Abstract | Preprint (not certified by peer review)
9. Gu Z, Cheng B, Liu J, et al. **Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study.** *Respir Res*. 2020. **21**(1): 195-5.
PubMed Abstract | Preprint (not certified by peer review)
10. Barty M, Abdhaye A, Adnan A, et al. **Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a SARS-CoV Endermic Area.** *Respiratory Care*. 2020. **65**(2): 214-221.
PubMed Abstract | Preprint (not certified by peer review)
11. Ma S, Cai X, Chen Z, et al. **Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China.** *Int J Infect Dis*. 2020. **96**: 581-7.
PubMed Abstract | Preprint (not certified by peer review)
12. Sun J, Wang Q, Zhang D, et al. **Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.** *Signal Transduct Target Ther*. 2020. **5**(1): 31.
PubMed Abstract | Preprint (not certified by peer review)
13. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
14. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
15. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
16. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
17. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
18. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
19. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
20. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
21. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
23. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
24. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
25. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
26. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
27. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
28. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
29. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
30. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
31. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
32. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
33. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
34. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
35. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
36. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
37. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
38. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
39. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
40. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
41. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
42. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
43. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
44. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
45. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
46. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
47. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
48. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
49. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
50. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
51. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
52. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
53. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
54. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
55. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
56. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
57. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
58. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
59. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
60. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
61. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
62. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
63. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
64. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
65. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
66. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
67. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
68. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
69. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
70. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
71. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
72. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
73. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
74. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
75. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
76. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
77. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
78. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
79. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
80. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
81. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
82. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
83. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
84. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
85. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
86. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
87. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
88. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
89. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
90. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
91. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
92. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
93. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
94. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
95. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
96. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
97. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
98. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
99. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>
100. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281141/>

Characteristic	n	n (%)	n	n (%)	n	n (%)	n	n (%)	p value
Smoker (n, %)	5	2.3	2	0.9	0	0	2	3.2	0.1
COPD (n, %)	1	0.4	0	0	0	0	1	0.4	0.1
Liver disease (n, %)	0	0	0	0	1	0.5	1	0.5	0.2
Respiratory Failure (n, %)	0	0	0	0	15	15.7	31	19.7	<0.05
Ventilator (n, %)	0	0	0	0	12	10.5	21	19.7	<0.05
Sepsis (n, %)	0	0	0	0	17	14	17	14	0.006
Type of bacterial infection									
<48 hours (n, %)(Co-infection)	4	1.8	3	1.4	6	2.8	13.0	6.0	0.52
>48 hours (n, %)(Secondary infection)	22	10.1	16	7.3	18	7.3	54.0	24.8	
Bacterial Infection (n, %)	15	6.9	12	5.5	16	7.3	43.0	19.7	0.55
Antibiotic use (n, %)									
Yes	90	41.3	44	20.2	30	13.8	164.0	75.3	
Symptom and Duration									
Dyspnea (% days)	19.27	8.00	7.34	3.00	14.68	3.20	31.29		
Fever (% days)	16.97	6.40	3.27	1.00	2.75	0.80	22.93		
Cough (% days)	7.34	3.60	3.27	1.00	0.92	0.30	11.67		
Malaise (% days)	7.34	2.60	0.92	0.30	2.29	0.80	10.55		

Pathogens associated with a bacterial infection

We collected 110 culture samples from suspected bacterial infection patients, consisting of 44 blood samples, nine urine samples, and 57 sputum samples. Among them, bacteria were detected in nine blood cultures, four urine cultures, and 17 sputum cultures. Sputum samples were collected, some from spontaneous sputum (n=47) and the others from endotracheal tube aspirate (n=10). Gram-negative bacteria dominate the culture result (70.37%). Bacteria found in the blood were extended-spectrum β -lactamase (ESBL)-producing *Klebsiella pneumoniae* (2), *Pseudomonas fluorescens* (1), *Pseudomonas putida* (1), *Staphylococcus epidermidis* (2), *Staphylococcus haemolyticus* (1), *Staphylococcus hominis* (2). Bacteria found in urine were ESBL-producing *Escherichia coli* (2), *Enterococcus faecalis* (1), and *Pseudomonas putida* (1). There were 47 isolates found in sputum cultures, in which six of them were fungi (*Can-dida spp*). The most frequent bacteria found was *Acinetobacter baumannii* (9), followed by *Klebsiella pneumoniae* (5), *Pseudomonas aeruginosa* (4), *Escherichia coli* (2), *Enterobacter cloacae complex* (3), and *Staphylococcus haemolyticus* (3) (see Table 3 and Figure 3).

Table 3. Result of microbiological culture.

Culture	Number
Sputum	57
<i>Acinetobacter baumannii</i>	9
<i>Candida spp</i>	6
<i>Klebsiella pneumoniae</i>	5
<i>Pseudomonas aeruginosa</i>	4
<i>Enterobacter cloacae complex</i>	3
<i>Staphylococcus haemolyticus</i>	3
<i>Streptococcus mitis / Streptococcus oralis</i>	3
<i>Escherichia coli</i>	2
<i>Escherichia coli (ESBL)</i>	1
Others	11

In this section please correct (*Can-dida spp*) to (*Candida spp*). I can not make corrections and highlight them because they change the structure of PDF.

0.033), basal urea nitrogen (BUN) ($p = 0.007$), alanine aminotransferase (ALT) levels ($p = 0.01$) were significantly higher in either severe or critically ill COVID-19 patients than moderate cases. We also found a lower lymphocyte count ($p = 0.001$) and PdL_1 , F_1C_0 , ino ($p = 0.005$) in either severe or critically ill COVID-19 patients than moderate cases. The procalcitonin level significantly increased in severe and critical illness conditions. The CRP level also increased but was not statistically significant. The majority of patients (82.9%) were recovered and discharged from the hospital, while 9.8% of the patients died. Most of the patients who died were in critically ill condition at presentation to hospital.

Bacterial infections

Bacterial infection was confirmed in 41 patients (19.7%) (see Table 2). There were no sex differences between bacterial infections and no bacterial infection patients. Patients with a bacterial infection have an older mean age than no bacterial infections, although.

Table 2. Comparison of COVID-19 patients who had bacterial infections and without bacterial infections.

	Bacterial Infection	No Bacterial Infection	Total (n, %)	p value			
	41	175	216	100			
Sex							
Male (n, %)	20	29.85	130	45.90	120.00	75.75	0.25

the two categories. COVID-19 patients with bacterial infections had a longer hospital length of stay, a higher proportion of respiratory failure, ICU treatment, ventilator use.

Mortality occurs in 16.28% of COVID-19 patients with bacterial infections, higher than those without bacterial infections (9%). Overall, COVID-19 patients with bacterial infection had a worse prognosis than those without bacterial infection (p<0.04).

The empirical antibiotic was given to 75.29% of the patients. Antibiotics used in these patients were quinolones (60.1%), cephalosporins (28.44%), carbapenem (23.85%), and aminoglycosides (4.59%). Quinolone used in these patients was mostly levofloxacin (79.39%), and the others were moxifloxacin (20.61%). The carbapenem used in this study was meropenem. Cephalosporins used were ceftriaxone, cefazidime, cefotaxime, cefepime/zolactam, and cefuroxime (see Figure 1).

Confirmation the following details :

- All author names are spelled correctly (confirmed)
- Authors are listed in the correct order (confirmed)

- Affiliations for all authors are accurate (confirmed)
- The information in the Copyright section is correct (confirmed)
- All figures and figure legends are correct (Not correct --> still need correction for some section as I said before)
- All external files, including data files are correct (confirmed)
- All links within the article are working, and correct (confirmed)

If you still dont clear about my correction I have made, please contact me soon. I hope pre PDF proof are sent back to me once again for I convince that article published is no more mistake.

Thank you

Best regards

Tri Pudy Asmarawati



Virus-free. www.avg.com

Pada tanggal Sen, 8 Feb 2021 pukul 19.06 <production@f1000research.com> menulis:

Dear Tri Pudy

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya
Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, Arifianto MV, Bramantono B *et al.*

Please click [here](#) to download the PDF proof of your F1000Research article.

Please mark on the PDF where Tables 2 & 3 and Figure 2 should be cited in the main text.

Please look through the article and let me know if it requires any corrections or if you are happy for it to be published as it is. Please also confirm the following details are correct:

- All author names are spelled correctly
- Authors are listed in the correct order
- Affiliations for all authors are accurate
- The information in the Copyright section is correct
- All figures and figure legends are correct
- All external files, including data files are correct
- All links within the article are working, and correct

Please note that connecting an ORCID account to F1000Research requires the account holder to sign in to both F1000Research and ORCID, **therefore it isn't possible for us to add ORCID badges for your co-authors on their behalf.** When the article is published, they will receive an email encouraging them to connect their ORCID account to F1000Research. If they do this, their ORCID badge will be displayed next to their name.

Corrections at this stage may require further typesetting and therefore cause some delays. If any corrections are necessary, please mark them directly on the PDF file using the commenting and markup tools in software such as Adobe Reader.

Please return your proof corrections to us via email - please note that after the article has been published, any requests for minor corrections will only be considered on a case-by-case basis. Therefore, we encourage you to check your proofs carefully at this stage.

If there are any outstanding queries on your reviewer suggestions, then we will be in touch with you shortly.

Best regards,

Mahnoor
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.
Do not delete (filing code): F1KR00CDE F1R-VER34701-A (end code)

Information Classification: General